SCHEMBL1751897

SCHEMBL1751897

O=C(OC1C(=O)OC(=O)C1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
F2 P00734 1/20 0.48
PPM1B O75688 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
TSHR P16473 2/20 0.45
KMT2A Q03164 4/20 0.44
MAPK1 P28482 1/20 0.44
HIF1A Q16665 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
CHRNA7 P36544 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 2/20 0.42
GAA P10253 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL636837 1.00 LMNA (0.48) LMNAF2PPM1BTDP1TSHR
SCHEMBL637664 1.00 LMNA (0.48) LMNAF2PPM1BTDP1TSHR
SCHEMBL8458023 0.81 TDP1 (0.50) LMNATDP1KMT2ASMN1; SMN2MAPT
SCHEMBL5692175 0.81 TDP1 (0.50) LMNATDP1KMT2ASMN1; SMN2MAPT
SCHEMBL2969544 0.81 TDP1 (0.50) LMNATDP1KMT2ASMN1; SMN2MAPT
SCHEMBL8461105 0.80 PARP1 (0.46) TDP1TSHRKMT2AMAPTALDH1A1
SCHEMBL2244028 0.77 GAA (0.50) LMNAF2TDP1TSHRKMT2A
SCHEMBL8965206 0.77 GAA (0.50) LMNAF2TDP1TSHRKMT2A
SCHEMBL23710673 0.76 MEN1 (0.42) LMNAF2PPM1BKMT2ACHRNA7
SCHEMBL9618911 0.76 BCHE (0.48) KMT2ACHRNA7MAPTMEN1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110452258-A A kind of preparation method of dipeptides valine Boroproline salt BALMXY PHARMACEUTIC CO LTD 2019-11-15 CN claimed
US-4259383-A PEROXY COMPOUNDS STERLING DRUG INC. (US) 1981-03-31 US claimed
US-7968748-B2 Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest ABIOGEN PHARMA S.P.A. (IT) 2011-06-28 US disclosed
US-20090292129-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST ABIOGEN PHARMA S.P.A. (IT) 2009-11-26 US disclosed
EP-1986996-A2 A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST Abiogen Pharma S.p.A. (IT) 2008-11-05 EP disclosed
WO-2007088571-A2 A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST ABIOGEN PHARMA S.P.A. (IT) 2007-08-09 WO disclosed
WO-2006050472-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF 3-AMINOPROPYLPHOSPHONOUS AND -PHOSPHINIC ACIDS XENOPORT, INC. (US) 2006-05-11 WO disclosed
JP-2003335766-A METHOD FOR PRODUCING DIBENZOYLTARTARIC ACID AND ACID ANHYDRIDE THEREOF NIPPON LIGHT METAL CO LTD 2003-11-28 JP disclosed
EP-0600714-B1 Process for producing O,O'-diacyltartaric anhydride and process for producing O,O'-diacyltartaric acid TORAY INDUSTRIES (JP) 1999-08-18 EP disclosed
EP-0924188-A1 Production of 0,0'-diacyltartaric acid crystals TORAY INDUSTRIES, INC. (JP) 1999-06-23 EP disclosed
EP-0772594-A1 IMINOXYCARBOXYLATES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS Abbott Laboratories (US) 1997-05-14 EP disclosed
WO-1996002507-A1 IMINOXYCARBOXYLATES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1996-02-01 WO disclosed
US-5451687-A Process for producing O,O'-diacyltartaric anhydride and process for producing O,O'-diacyltartaric acid TORAY INDUSTRIES, INC. (JP) 1995-09-19 US disclosed
EP-0600714-A1 Process for producing O,O'-diacyltartaric anhydride and process for producing O,O'-diacyltartaric acid TORAY INDUSTRIES, INC. (JP) 1994-06-08 EP disclosed
EP-0256586-B1 PROCESS FOR THE PREPARATION OF ESTERS OF 4-(2,3-EPOXYPROPOXY)PHENYLACETIC ACID AND 4-(2-HYDROXY-3-ISOPROPYLAMINO-PROPOXY)PHENYLACETIC ACID AND/OR ATENOLOL IN STEREOSPECIFIC FORM GIST-BROCADES N.V. (NL) 1992-05-13 EP disclosed
EP-0256586-A1 Process for the preparation of esters of 4-(2,3-epoxypropoxy)phenylacetic acid and 4-(2-hydroxy-3-isopropylamino-propoxy)phenylacetic acid and/or atenolol in stereospecific form GIST-BROCADES N.V. (NL) 1988-02-24 EP disclosed
US-4318819-A Chiral supports for resolution of racemates UOP INC. (US) 1982-03-09 US disclosed
US-4318820-A Chiral supports for resolution of racemates UOP INC. (US) 1982-03-09 US disclosed
US-4259383-A PEROXY COMPOUNDS STERLING DRUG INC. (US) 1981-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292129-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST SRR, EPHX2, ALOX5 LMNA 715/4885F2 153/4885PPM1B 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.